Atrial fibrillation (AF) is the most common cardiac arrhythmia and is associated with an increased risk of stroke, heart failure, and mortality [1]. Many cases of AF remain undetected due to no or subtle symptoms – a condition called device-detected AF [1]. This has increased the interest in systematic AF screening to prevent stroke via early detection and anticoagulation. Previous studies found even short-lasting device-detected AF to be associated with increased stroke risk [2], that potentially can be reduced with anticoagulant treatment, although, at the cost of increased bleeding risk, that may tip the net benefit balance towards harm [3–5].
